source
- Teva R&D chief Eric Hughes resigns, company taps innovative medicines head as interim leadTeva announced that its chief scientific officer for research and development, Eric Hughes, M.D., Ph.D., will leave the company. Hughes, who joined Teva in 2022 as executive vice president of globa…
- Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlookNovartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…